For over 30 years, PAREXEL has proven to be a trusted partner for the complex development journey required of biopharmaceutical and medical device companies. We’re also an astute guide, able to simplify that journey for our clients, so safe new products can reach patients more quickly.
Josef H. von Rickenbach (Chairman of the Board and Chief Executive Officer)
Mark A. Goldberg, M.D. (President and Chief Operating Officer)
Headquartered near Boston, Massachusetts, PAREXEL operates in 86 locations in 51 countries around the world, and has 19,370 employees. PAREXEL strives to be the premier provider to the biopharmaceutical and medical device industries for the development and commercialization of new medical therapies worldwide.
We provide the most comprehensive drug development capabilities of any CRO worldwide. Our global regulatory expertise, Phase I-IV clinical research services, integrated eClinical technologies, and advanced commercialization services all work together to move you through the development journey more smoothly and cost-effectively from beginning to end.